Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06365619 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

Study acronym: NeoRelapse
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Jul 2026 to Oct 2026 Primary endpoints: details revised at 1 of 1 entry · Eligibility criteria expanded, about 49 words · Secondary endpoints: details revised at 2 of 5 entries · 1 more Show 4 more changesShow less
    • Primary endpoints: details revised at 1 of 1 entry
    • Eligibility criteria expanded, about 49 words
    • Secondary endpoints: details revised at 2 of 5 entries
    • Publications: details revised at 31 of 31 entries
  2. Start date: Jun 2026 to Jul 2026 Eligibility criteria expanded, about 1 wordv10 Show 1 more changeShow less
    • Eligibility criteria expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  3. Primary completion pushed from Aug 2026 to Aug 2027 Start date: Feb 2026 to Jun 2026 · Completion pushed from Aug 2029 to Aug 2030 · Eligibility criteria shortened, about 19 words · 1 morev9 Show 4 more changesShow less
    • Start date: Feb 2026 to Jun 2026
    • Completion pushed from Aug 2029 to Aug 2030
    • Eligibility criteria shortened, about 19 words
    • Site contact updated

    See this version in full on ClinicalTrials.gov ↗

  4. Start date: Dec 2025 to Feb 2026v8
  5. Start date: Jun 2025 to Dec 2025v7
Show 5 earlier versionsHide 5 earlier versions
  1. Start date: Apr 2025 to Jun 2025v6
  2. Start date: Feb 2025 to Apr 2025v5
  3. Start date: Nov 2024 to Feb 2025v4
  4. Re-verified, no change to tracked fieldsv3
  5. Trial status: Not Yet Recruiting to Recruiting Start date: Aug 2024 to Nov 2024 · Site details revisedv2 Show 2 more changesShow less
    • Start date: Aug 2024 to Nov 2024
    • Site details revised
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University of Utah
302 trials monitored
See 17 trials at risk
Melanoma
1,026 trials monitored
See 48 trials at risk
The goal of this clinical trial is to study the impact of Neoadjuvant ipilimumab and nivolumab for melanoma patients that had recurrence during or after adjuvant anti-PD-1 therapy. Participants will receive 2 cycles of treatment prior to their standard of care surgery. After surgery participants will receive standard of care adjuvant therapy and be followed for response.
Trial Details
NCT Number NCT06365619
Lead Sponsor University of Utah
Conditions Melanoma
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov